Turning to the AMPLIFY study with apixaban, a total of 4816 patients with DVT or PE were enrolled into a single study (Figure 13).[11]  The comparator was the classic therapy of enoxaparin followed by a vitamin K antagonist.  AMPLIFY was a double-blind trial, very similar to the EINSTEIN studies in that it employed the same single-drug approach.  Apixaban was given at a dose of 10 mg bid for the first week, followed by a dose reduction to 5 mg.  The primary efficacy outcome was symptomatic recurrent VT or VTE-related death, identical to the previous studies, but the safety outcome was bleeding during study treatment.   Buller HR. Am J Med 2013; published on-line at http://education.amjmed.com/00000.